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Sumrlrlary 
Peptide MAGE-1.A1  is a nonamer derived from protein MAGE-1 that can associate with the 
HLA-A1  molecule.  It was  shown  previously to  be recognized by an  antitumor  cytolytic T 
lymphocyte (CTL) clone derived from the blood of melanoma patient MZ2. We derived two 
other  anti-MAGE-1.A1  CTL clones  from different blood  samples of the  same  patient  and 
compared  the  fine  specificity of recognition  of the  three  CTL by testing  them  on  variant 
MAGE-1.A1  peptides incorporating different amino  acid substitutions.  The  epitopes recog- 
nized by the CTL proved to be different. While modifications of residues at positions 5, 6, or 7 
in the antigenic peptide affected recognition by the three CTL, each of the modifications of 
residues at positions 1, 4, or 8 affected recognition by one CTL only. The sequences of both 
the 0~ and [3 chains of the T  cell antigen receptor of the three CTL were completely different. 
The results indicate a long-lasting diversity in terms of fine specificity and of T  cell antigen re- 
ceptor structure in the repertoire ofantitumor CTL derived from the blood of a melanoma pa- 
tient and directed against a defined tumor antigen. 
W 
hen blood lymphocytes of melanoma patient MZ2 
are stimulated in vitro with autologous tumor cells 
in  the  presence of IL-2, they proliferate and  differentiate 
into  cytolytic T  lymphocytes (CTL) 1 that specifically rec- 
ognize the melanoma cells (1). A large panel of tumor-spe- 
cific MHC class I-restricted CTL clones derived from the 
effector cells were shown to recognize at least six different 
antigens on melanoma line MZ2-MEL (2). This multiplic- 
ity of antigens recognized by autologous CTL clones was 
also observed with two other melanoma lines that could be 
studied in detail, SK29-MEL and LB33-MEL (3, 4). 
Several antigens recognized by CTL on MZ2-MEL cells 
have been  identified.  Antigens  MZ2-E  and  -Bb  are  two 
different peptides derived from a protein encoded by gene 
MAGE-1  and  presented  by  the  MHC  class  I  molecules 
HLA-A1 and HLA-Cw*1601, respectively (5-7). Antigen 
MZ2-D is a peptide also  presented by HLA-A1, which  is 
encoded  by  gene  MAGE-3  (8),  another  member of the 
1Abbreviations used in this paper: BMC, blood mononuclear cell; CTL, cy- 
tolytic T lymphocytes; IASA, iodo, azido salicylic acid; LY5~, 50% of 
maximal lysis. 
MAGE  gene family that  comprises at least  12  highly ho- 
mologous genes (9). Antigen MZ2-Ba is a peptide encoded 
by  gene  BAGE  and  presented  by  HLA-Cw*1601  (10). 
Antigen  MZ2-F  is  a  peptide  encoded  by gene  GAGE-1 
and presented by HLA-Cw6  (11).  Genes MAGE,  BAGE, 
and GAGE are normal genes that are not expressed in nor- 
real tissues,  with the exception of testis,  but are expressed 
in a variety of tumors of different histological types. Antigen 
MZ2-C  is  a peptide  encoded  by the  tyrosinase gene  and 
presented by HLA-B44 (Brichard,  V., J.  Herman, A. Van 
Pel,  C.  Wildmann,  B.  Gaugler,  T.  Boon,  and  B.  Leth6, 
manuscript in preparation). In contrast to the former group 
of genes, the tyrosinase gene is expressed in melanocytes as 
well as in melanoma cells. 
Antigen  MZ2-E  or  MAGE-1.A1,  thus  defined  as  the 
nonapeptide  161-169  derived from protein MAGE-1  and 
bound to HLA-A1  (6),  was recognized by 7 out of a col- 
lection of 70 tumor-specific CTL clones derived from mel- 
anoma patient  MZ2  (2).  Moreover,  when limiting num- 
bers  of  MZ2  blood  mononuclear  cells  (BMC)  were 
stimulated with autologous tumor cells to estimate the fre- 
quency of precursors of antitumor CTL (CTL-P),  1/7,000 
BMC  were  anti-MZ2-MEL-specific  CTL-P  (12),  and 
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P. G., unpublished observations). Together, these data sug- 
gest  that  10%  of the  antitumor CTL of patient MZ2  are 
specific  for  antigen MAGE-1.A1.  We  wished  to  analyze 
the diversity of this CTL response in terms of both the fine 
specificity of antigen recognition and of the primary struc- 
ture of the TCR ot and 13 chains. 
Materials and Methods 
Patient and Tumor Cell Line.  Melanoma cell line MZ2-MEL 
was established in 1982 from an adrenal metastasis of patient MZ2 
(1). The patient remains disease free  since  1983  after  cytostatic 
chemotherapy and surgical removal of multiple lymph node and 
visceral metastases (Knuth, A., personal communication). She was 
repeatedly  vaccinated with  mutagenized and lethally  irradiated 
autologous melanoma cell clones from 1983 on (2). 
Derivation and Culture Of CTL Clones.  The obtention of anti- 
MZ2-E  CTL  clone  82/30  has  been  described  previously (1). 
Clone 253/47  was  obtained as  follows.  BMC  of patient MZ2 
were labeled with fluoresceinated  anti-CD813 mAb 1A3.3 (a gift 
of Dr. D. Olive, Imtitut Paoli Calmette and lnstitut National de 
la  Sant6  et  de  la  Recherche  Medicale  Unit6  211,  Marseille, 
France), and CD8 § lymphocytes were sorted on a flow cytometer 
(ATC3000; ODAM, Wissembourg, France).  They were seeded 
(1,000/well)  in  V-bottom microwells  (Nunc,  Roskilde,  Den- 
mark)  and stimulated with  irradiated  (100  Gy  from  a  cesium 
source)  autologous MZ2-MEL.3.1  melanoma cells (3,000/well) 
in a total volume of 100 /~1 of lscove's medium (GIBCO BRL, 
Gaithersburg, MD)  supplemented with L-arginine (0.55  raM), 
g-asparagine (0.24 raM), L-glutamine (1.5 raM), 2-ME (5 ￿  10 -5 
M),  10% human serum, 10 U/ml of human rlL-2 (a gift of Bio- 
gem  Geneva, Switzerland),  and 5 U/ml of human rlL-4 (a gift 
from Dr. R. Devos, Roche Research Center, Ghent, Belgium). 1 
U/ml of IL-2 is defined as the concentration that gives 50% max- 
imal proliferation  of CTLL-2. 1 U/ml of IL-4 is the concentra- 
tion that gives 50% maximal proliferation of human T cells previ- 
ously  activated  with  PHA.  On  day  7,  the  microcultures were 
restimulated  by addition of 100 ~1 of medium (of the same com- 
position as on day 0) containing 3,000 irradiated  tumor cells. On 
day 15, aliquots of the responder cells were transferred into other 
microwells  to test their lyric activities. The remaining cells were 
restimulated  as on day 7.  On day 21,  aliquots  of responder cells 
were used again for lysis assays, and microcultures that exerted  a 
strong anti-MZ2-E lytic activity were identified.  The remaining 
responder cells from  these  selected  clones,  among them  clone 
MZ2-CTL-253/47, were transferred  on day 23 into 2-ml wells 
(Nunc) and were stimulated by the addition of irradiated autolo- 
gous tumor cells (10S/well) and irradiated LG2-EBV-B cells (106/ 
well)  as feeder  cells, in medium identical to the previously de- 
scribed  one except  with a higher concentration  of IL-2 (50 U/ 
ml).  Long-term culture of the  CTL  clone was  pursued as  de- 
scribed (1). 
Synthetic Peptides and CTL Assays.  Peptides  were synthesized 
on solid phase using Fmoc for transient NH2-terminal protection 
as described  (8) and characterized  by mass spectrometry.  All pep- 
tides  were  >90%  pure as  indicated by analytical  HPLC.  Lyo- 
philized peptides  were  dissolved  in 20  mM  PBS  and stored  at 
-20~  Lysis of target cells by established CTL clones or by mi- 
crocultures  was tested by chromium release assay using standard 
procedures (8). Target cells were 51Cr labeled for  1 h at 37~  in 
the presence of anti-human class I MHC mAb W6/32 (13) in the 
form of hybridoma culture supernatant and washed  three times. 
Target cells (1,000 cells in 50 t*1) were then incubated in V-bot- 
tom microwells in the presence  of various concentrations of pep- 
tide (100 I*1) for 15 rain at room temperature. CTL were then 
added  (10,000  cells in 50  ~,1), and chromium release was mea- 
sured after 4 h at 37~ 
Cloning and Sequencing of TCR.  Total RNA from 106 cells of 
each clone was extracted  as described (14) and reverse transcribed 
using a  poly-dT primer  and  reverse  transcription kit  reagents 
(Boehringer Mannheim, Mannheim, Germany). Aliquots  of the 
eDNA were amplified by PCR in separate tubes using a panel of 
V{x- or V[3-specific oligonucleotides and a Ca- or C]3-specific 
oligonucleotide (15). PCR amplification was carried  out on an 
automate (9600; Perkin-Elmer Cetus Instruments, Norwalk, CT) 
and comprised a 30-s denaturation step at 94~  followed  by 4() 
cycles of 25 s at 94~  45 s at 60~  and 45 s at 72~  10 I*1 of 
PCR products was loaded on a 2% agarose gel and electrophore- 
sed. Amplified DNA  was  electroeluted and either  directly  se- 
quenced (16) or cloned in the pCRTM vector according to the 
TA cloning kit procedures  (lnvitrogen, San Diego,  CA).  Upon 
electroporation in Escherichia coli OneShot INVoeF' strain (lnvit- 
rogen),  plasmid  DNA  of recombinant colonies  was  prepared 
(QIAGEN Inc., Chatsworth, CA)  and sequenced using the Se- 
quenase kit (2.0; United States Biochemical,  Cleveland, OH). 
Modeling of the HLA-A1/MAGE-1.A1  Peptide Complex.  The 
structure  of the complex was modeled using the ProMod package 
developed by M.  Peitsch  (17). Briefly,  an averaged  framework 
was  constructed from  the  experimentally defined structures  of 
cocrystals of HLA-A2 with  defined antigenic peptides  (18), of 
HLA-B27 (19), of HLA-A68 with an influenza peptide (20), and 
of H-2K  b (21) (Brookhaven Protein Databank, Brookhaven Na- 
tional Laboratory,  Upton, NY). The aligned HLA-A1  sequence 
was  fitted  on this  framework,  and the  most likely positions  of 
polymorphic amino acid  side  chains  were  determined by scan- 
ning for sterically unhindered conformations consistent with local 
secondary structure.  The initial conformation of the MAGE-1.A1 
peptide backbone was similarly predicted from those of influenza 
matrix M1  58-66, HTLV-1 Tax 11-19,  hepatitis B nucleocapsid 
18-27, and HIV gp120  197-205 peptides bound to HLA-A2 (18). 
The optimal position of the peptide within the binding groove 
was calculated by rigid body minimization, and the HLA-peptide 
complex was  then  relaxed  without constraints  by 500  steps of 
Powell minimization. The stability of the final calculated confor- 
mation  was  verified  by  simulated  annealing after  heating  to 
300~  using standard molecular dynamics methods. Energy min- 
imizations were  carried  out using the X-PLOR program  (Axel 
Bri.inger, Yale University, New Haven, CT). 
Results 
When peripheral  blood lymphocytes of melanoma pa- 
tient MZ2 were stimulated in vitro with irradiated autolo- 
gous tumor cells in the presence of IL-2, a strong lympho- 
cyte  proliferation was  observed that was  accompanied by 
the development of a cytolytic activity directed against the 
stimulator cells (1).  The effector lymphocytes were cloned 
by limiting dilution, and several CTL clones were derived 
that showed specificity for the autologous melanoma clonal 
line MZ2-MEL.43. One of these CTL clones, MZ2-CTL- 
82/30, was shown to recognize one of the several antigens 
expressed by the  tumor cells and named antigen MZ2-E 
(2).  CTL 82/30 recognizes the nonapeptide MAGE-1.A1, 
1020  MAGE-1.A1--specific TCR Repertoire encoded  by  gene  MAGE-1  and  presented  by  HLA-A1 
molecules (5, 6). 
Derivation of New Anti-MAGE-1.A1  CTL from  Patient 
MZ2.  To study the  diversity of anti-MAGE-1.A1  CTL 
in melanoma patient MZ2, we derived other anti-MAGE- 
1.A1  CTL clones from blood lymphocytes obtained from 
the patient 8 yr after the derivation of CTL 82/30.  Several 
hundred microcultures were set up in which limited num- 
bers of CD8 + lymphocytes were stimulated either with ir- 
radiated autologous tumor cells  (experiment 253)  or with 
autologous  BMC  incubated  with  peptide  MAGE-1.A1 
(experiment 258),  in the  presence of IL-2. After three  or 
four rounds of weekly stimulation, the microcultures were 
tested for their ability to lyse the MHC class 1-negative B 
cell  line  CIR  transfected  with  HLA-A1  and  incubated 
with  peptide  MAGE-1.A1.  The  lyric  activities  of CTL 
clones  253/47  and  258/8  are  shown  in  Fig.  1,  together 
with that of CTL clone 82/30.  All three CTL lyse MZ2- 
MEL.43  cells  but  not  the  E-  antigen-loss  variant  MZ2- 
MEL.2.2  cells,  which  do  not  express  gene  MAGE-1. 
However, the three CTL lyse E- cells incubated with pep- 
tide  MAGE-1.A1,  or  E-  cells  transfected  with  gene 
MAGE-1. These results indicate that the three CTL recog- 
nize the same antigen. 
Absence of Recognition of Homologous M_AGE  Peptides by 
Anti-MAGE-1.A1  CTL.  Gene  MAGE-1  belongs  to  a 
family of at least 12 related genes, of which 6 are expressed 
in  a  number  of tumors  of various  histological  types  (9). 
Several of the MAGE polypeptide sequences contain non- 
apeptides  with  various  degrees  of homology to  the  anti- 
genic MAGE-1.A1  peptide  (Table 1). With the exception 
of the  MAGE-2  peptide,  all  these  peptides  contain  the 
Table  1.  MA GE Nonapeptides Homologous to the M_AGE-1 
Antigenic Peptide 
MAGE-1  E  A  D  P  T  G  H  S  Y 
MAGE-2  E  V  V  P  I  S  H  L  Y 
MAGE-3  E  V  D  P  I  G  H  L  Y 
MAGE-4a  E  V  D  P  A  S  N  T  Y 
MAGE-4b  E  V  D  P  T  S  N  T  Y 
MAGE-6  E  V  D  P  I  G  H  V  Y 
Amino acid sequences corresponding to MAGE-1  161-169,  MAGE-2 
168-176, MAGE-3 168-176, MAGE-4a 168-176, MAGE-4b 169-177, 
and MAGE-6 168-176 (9). 
HLA-A1 binding motif consisting of Asp in position 3 and 
Tyr in position 9  (22-24).  Using a competition assay, we 
found  that,  with  the  exception  of the  MAGE-2  peptide, 
the peptides listed in Table 1 could indeed efficiently bind 
to HLA-A1 (8), but none of them sensitized HLA-A1 + tar- 
get cells to lysis by any of the three anti-MAGE-1.A1  CTL 
clones, illustrating the exquisite specificity of these CTL for 
the MAGE-1.A1 peptide (not shown). 
Differential Recognition of MA GE- 1.A 1/MAGE-3.A 1 Hy- 
brid  Peptides.  HLA-Al-restricted  CTL  clones  were  ob- 
tained  that  recognize  a  MAGE-3  peptide,  designated 
MAGE-3.A1, that is homologous to the MAGE-1.A1 pep- 
tide  (8).  As mentioned above, the anti-MAGE-1.A1  CTL 
do  not  recognize  peptide  MAGE-3.A1,  and  the  anti- 
MAGE-3.A1  CTL conversely failed to  recognize  peptide 
MAGE-1.A1  (8).  Peptides MAGE-1.A1  and MAGE-3.A1 
differ at positions 2, 5, and 8 (Table 1). 
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Figure  1.  Lytic  activities  of three  independent 
anti-MAGE-1.A1  CTL clones of melanoma patient 
MZ2.  Avti-MAGE-1.A1  CTL  clone  MZ2-CTL- 
82/30 was obtained previously by stimulating blood 
lymphocytes of patient MZ2 with autologous mela- 
noma cells. CTL clones 253/47 and 258/8 were ob- 
tained by stimulating CD8 § blood lymphocytes with 
autologous tumor cells or with autologous BMC in- 
cubated  with  peptide  MAGE-1.A1,  respectively. 
Target  cells  included  the  clonal  melanoma  line 
MZ2-MEL.43,  the  E-  antigen-loss  variant  cells 
MZ2-MEL.2.2,  which  lost  expression  of  gene 
MAGE-1, the E-  cells in the presence of 1 txM of 
peptide MAGE-1.A1, and the clonal cell hne MZ2- 
MEL.ET.1,  obtained  after  transfection of E-  cells 
with gene MAGE-1. Table 2.  Recognition  of Variant MA GE- 1 Peptides by Different CTL Clones 
Relative antigenic activity of variant MAGE-1 peptides* 
MAGE-1 
CTL clone  161-169  E161  D163  P164  T165  Gl66  H167  $168  Y169 
[pM] 50~ 
253/47  100  <0.0001  <0.000l  0.3  0.02  <0.0001  <0.0001  0.5  <0.0001 
82/30  100  0.4  <0.0001  <0.0001  0.003  0.0001  0.0l  5  0.0006 
258/8  130  1  <0.0001  I  0.02  <0.0001  <0.0001  <0.0001  <0.0001 
*The amino acid residue on top of each column (single-letter  code) represents the residue substituted by Ala. The antigenic activity for both the 
eight single-Ala  substituted MAGE-1 nonapeptides and the unsubstituted MAGE-1 peptide was determined in a SlCr-release  assay. The lymphocyte 
to target cell ratio was 10:1. Threefold dilutions for each peptide were made in a concentration range from 10 -6 to  10 -12 M. The relative antigenic 
activity is calculated  as the concentration of the reference peptide MAGE-1.A1 161-169 required to obtain LYs~  ~  divided by that of the variant pep- 
tide. 
r  represent the concentration (picomolar, 10-12M) of the nonsubstituted MAGE-1.A1 161-169 nonapeptide required to obtain LYs0 by 
the corresponding CTL clones. This value was used as the reference concentration for calculation of the relative potency of all the other peptides 
included in this table. 
MAGE-1.A1/MAGE-3.A1  hybrid  peptides  were  syn- 
thesized that incorporated one or two substitutions at P2, 
P5,  or P8.  These hybrid peptides displayed similar HLA- 
Al-binding  activities. They were tested for recognition by 
the anti-MAGE-1.A1 CTL on cells of the MHC class I-neg- 
ative lymphoblastoid cell line C1R. transfected with HLA- 
A 1 (Fig. 2).  For CTL clone 253/47, all substitutions abro- 
gated  recognition, with  the  exception  of substitution of 
Leu for Ser at P8.  In contrast, for CTL clone 258/8,  the 
only tolerated substitution was  the replacement of Val for 
Ala at P2. For CTL clone 82/30, the pattern of recognition 
was  more  complex.  Similar to  CTL 253/47,  CTL  82/30 
recognized the substitution at P8, but it also recognized the 
substitution at P2, as well as, albeit with a lower efficiency, 
the simultaneous substitutions at P2 and P8. 
These  results indicate that  the  three  anti-MAGE-1.A1 
CTL displayed different fine specificities. In spite of these 
differences, all three  clones failed to  recognize any of the 
three  hybrid  peptides  containing the  substitution at  P5. 
Thus, the residue at P5 is critical for discrimination of the 
MAGE-1.A1 from the MAGE-3.A1 epitope. 
Differential Recognition of MA GE-1.A 1 Variant Peptides In- 
corporating Ala  Substitutions.  The  anti-MAGE-I.A1 CTL 
were tested on a panel of MAGE-1.A1 variant peptides that 
incorporated single Ala substitutions at each position. The 
effect of Ala substitution can be equated to the removal of 
most of the side chain at a given position without disturb- 
ing the overall peptide configuration. The substituted pep- 
tides bound to  HLA-A1  (8),  with the  exception of those 
with Ala at positions 3  or 9, which were shown to anchor 
antigenic peptides in HLA-A1 molecules (22-24). 
The relative antigenic activities of the  substituted pep- 
tides were measured for each  CTL  (Table 2).  Serial dilu- 
tions of each peptide were used to sensitize CIP,-A1 cells 
to lysis by CTL, and the concentration ofpeptide required 
to obtain 50% of maximal lysis (LYs0) was determined. To 
compare  the  LYs0  of a  given peptide  for  different  CTL 
clones, we expressed the results as relative antigenic activi- 
ties, which are the ratios between the LYs0 of the original 
peptide and that of the variant peptide. As expected, substi- 
tutions at HLA-A1 anchor positions 3 and 9 abrogated rec- 
ognition by all three CTL. Substitutions at PS, P6, and P7 
greatly reduced  the  efficiency of recognition by all three 
CTL as well. But other substitutions, substitution at Pl  for 
CTL  253/47,  at  P4  for  CTL  82/30,  and at  P8  for  CTL 
258/8, proved to abrogate the recognition by only one of 
the CTL (Table 2 and Fig. 3). Remarkably, the recognition 
of these substitutions was mutually exclusive. These results 
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Figure 2.  Recognition of MAGE-1.A1/MAGE- 
3.A1 hybrid peptides by the anti-MAGE-1.A1 CTL 
clones. 51Cr-labeled  C1R-A1 target cells were incu- 
bated with the indicated  concentrations  of the hybrid 
MAGE peptides and with the CTL clones at a lym- 
phocyte to target cell ratio of 10:1 for 4 h at 37~ 
The hybrid peptides are designated  by a code that in- 
dicates which substitution  was introduced in the se- 
quence; the number is the position of the substitu- 
tion,  the  first letter designates the  residue at  that 
position in the  original MAGE-1.A1 peptide, and 
the second letter designates the new residue at that 
position in the substituted peptide. -'-, EADPT- 
GHSY; -Q-, A2V; -A-, T51; -0-, S8L; -[~-, A2V 
+ T5I; -O-, T5I + S8L; -A-, A2V + S8L. T
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Figure 3.  Recognition of MAGE-1.A1 variant pep- 
tides with single Ala substitutions by the anti-MAGE- 
1.A1 CTL clones.  51Cr-labeled C1R-A1 target cells 
were incubated with the indicated concentrations of 
peptide MAGE-1.A1  ([]) or with analogues  incor- 
porating one Ala substitution at a time (O, A, or "k), 
and with the CTL clones at a lymphocyte/target cell 
ratio of 10:1 for 4 h at 37~ 
indicate  that  at  least  two  regions  of peptide  MAGE-1.A1 
are critical for recognition by the three CTL.  The first, rec- 
ognized by all CTL,  spans residues at positions 5,  6,  and 7. 
The other, different for each CTL,  is constituted by residue 
Pl,  P4, or P8. 
Sequences  of the  TCR  Used  by  Anti-MAGE-1.A1  CTL 
Clones.  As  expected  from  the  specificity  analysis  of the 
three CTL,  each of them expressed a different TCP,  (Table 
3). The gene segments used for both the tx and the [3 chains 
of the TCk  proved to  differ totally from one CTL  to  an- 
other,  with the exception of a J~39  segment used by both 
CTL  253/47  and 82/30.  Moreover,  the primary structures 
of the three TC1<  do  not share any common  feature,  nei- 
ther in  the  sizes  of their CDP,.3  equivalent regions  nor in 
their amino acid composition. 
Distribution  of the  Different  Anti-MAGE- 1.A I  Specificities 
in  Short-term  Cultures  of MZ2  Blood  CTL.  To  derive  a 
new  panel  of independent  anti-MAGE-1.A1  CTL  from 
patient MZ2,  600 miniature mixed lymphocyte  tumor  cell 
cultures were set up with CD8 + blood lymphocytes stimu- 
lated  with  autologous  melanoma  cells  in  the  presence  of 
IL-2 and IL-4.  These lymphocytes were collected from the 
Table 4.  Distribution of the Fine Specificities of Anti-MA GE-1.A 1 CTL in Short-Term Cultured MZ2 Blood Lymphocytes 
A.  Targets  Lysis by microcultures (%) 
C1R-AI+MAGE-1.A1  5  7  2  5  0  0  0  1  70  5  0  0  8  2  3  4  9  0  3  1  57  3  1  0 
C1R-Al+variant E1A  5  0  1  3  0  5  1  0  69  2  0  0  4  0  5  1  0  3  0  0  8  1  4  4 
ClR-Al+variant  P4A  3  5  3  3  3  0  0  0  68  0  0  0  9  0  0  1  0  2  2  0  58  0  {}  0 
C1R-Al+variant S8A  2  0  1  3  0  0  0  2  0  0  0  t  0  0  4  4  0  1  3  0  7  0  0  {t 
K562  5  2  1  2  1  0  1  0  0  2  {}  0  5  1  1  2  5  3  4  0  2  0  0  1 
B.  Peptides 
Number of microcultures 
MAGE-1.A1 peptide variant 
MAGE-I.A1  E161A  P164A  $168A  Specificity 
2  +  -  +  +  =  CTL 253/47 
7  +  +  -  +  =  CTL 82/30 
2  +  +  +  -  =  CTL 258/8 
4  +  -  +  -  =  other 
5  +  +  +  +  =  other 
(A) 600 microcultures were set up with sorted CD8 + blood lymphocytes from patient MZ2 (1,000 cells/well) stimulated with irradiated autologous 
melanoma cells MZ2-MEL.43  (3,000 cells/well) in the presence of IL-2 (10 U/ml) and IL-4 (5 U/ml). Microcultures were restimulated on day 7 
and 14 with stimulator cells, IL-2, and IL-4. On day 21, the lytic activities ofaliquots of all microcultures were tested on the indicated targets,  in the 
presence of a 50-fold excess of unlabeled K562 cells to inhibit the NK-like lytic activity. The lytic activities of 24 microcultures are shown. (B) The 
20 microcultures with a lytic activity against peptide MAGE-1 .A1 (> 15% lysis) were classified according to their pattern of lysis of C 1R.-A1 cells in- 
cubated with the variant peptides. The lytic activity against a variant peptide is reported as +  when it exceeded 50% of that measured against peptide 
MAGE  - 1.A 1. 
1024  MAGE-1.Al~specific TCI~ Repertoire patient 1 yr after those from which CTL 253/47 and 258/8 
were derived, and 7 yr after those from which CTL 82/30 
was derived. After three rounds of  weekly restimulation, all 
microcultures  were  tested  for  their  lytic  activity  against 
C1R-A1  cells previously incubated with peptide MAGE- 
1.A1  or with the three variant peptides incorporating Ala 
substitutions at positions P1, P4, or P8. An example of the 
lysis exerted by a small  number of these microcultures is 
shown  in  Table  4  A.  Among  all  microcultures,  20  that 
contained an anti-MAGE-1.A1  CTL could easily be iden- 
tified. These CTL could be classified  on the basis of their 
pattern  of recognition  of the  three  variant  MAGE-1.A1 
peptides (Table 4 B). Two, seven, and two CTL displayed 
a fine specificity corresponding to that of CTL 253/47, 82/ 
30, and 258/8, respectively. This indicated that these three 
types of CTL were consistently present in different batches 
of MZ2 blood lymphocytes, with a higher proportion of 
the 82/30 type. Two additional fine specificities were iden- 
tified among the nine other CTL, indicating that the reper- 
toire of anti-MAGE-1.A1  CTL in patient MZ2 may actu- 
ally comprise at least five independent fine specificities. 
Discussion 
Our results indicate that the repertoire of CTL directed 
against  tumor  antigen  MAGE-1.A1  in  melanoma  patient 
MZ2 is diverse both in terms of recognition of antigen and 
of TCR usage. The diversity of recognition of antigen was 
demonstrated for three independent CTL clones by analyz- 
ing their recognition of hybrid MAGE-1 .A1/MAGE-3.A1 
peptides  and  of a  set  of MAGE-1.A1  peptide  analogues 
containing  single  alanine  substitutions.  The  results  indi- 
cated  that  three  residues  (P5,  P6,  and  P7)  of peptide 
MAGE-1.A1  were  essential  for  recognition  by  all  three 
CTL, whereas each of residues at P1, P4, or P8 were rele- 
vant for only one CTL. Clones expressing these three dis- 
tinct fine specificities of recognition could be derived from 
blood  samples  obtained  from  patient  MZ2  several  years 
apart, suggesting that they were stable members of the pa- 
tient's T  cell repertoire. Moreover, testing additional anti- 
MAGE-1.A1  CTL clones for recognition of some of the 
Ala-substituted peptides indicated that the repertoire may 
actually comprise additional anti-MAGE-1.A1 specificities, 
which we did not characterize further. 
Attempting to visualize how CTL 253/47,  82/30,  and 
258/8 TCR  could interact with their antigen, we gener- 
ated a molecular model of peptide MAGE-1.A1 bound to 
the HLA-A1  molecule. Model building was based on the 
structures of cocrystals of HLA class I molecules with de- 
fined antigenic  peptides.  At  the  carboxy terminus  of the 
peptide, the side chain of Tyr-P9 is buried in the F pocket 
of the  HLA-A1  peptide-binding  site,  and  the  hydroxyl 
group  of its  aromatic ring presumably makes  a hydrogen 
bond with the carboxyl group of Asp116 from the floor of 
the  groove. The side  chain  of Asp-P3  also  points  down 
into the groove, and the model predicts that its carboxylate 
group  is  available  for  a  salt  bridge  with  the  positively 
charged side  chain of HLA-A1  Arg114 present in the  [~2 
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strand of the floor of the groove. Peptide residues Glu-P1, 
Pro-P4, Thr-P5,  Gly-P6, His-P7, and Ser-P8 side  chains 
appear to be more accessible  for direct interaction with the 
TCR (model not shown). 
On  the  basis of this  model,  it  is  conceivable that  the 
TCR of the three CTL clones analyzed in this study inter- 
act with the antigenic complex in distinct manners. Thus, 
the CTL 253/47 TCR might focus on the peptide portion 
comprised between its amino terminus and residue His-P7, 
and ignore changes affecting the side chain of the residue at 
PS. Conversely, the CTL 258/8 TCR might focus on the 
carboxy terminus of the peptide and ignore changes affect- 
ing the amino-terminal residues at P1  or P2.  Finally, the 
CTL 82/30  TCR  might focus on the  middle portion of 
the peptide, and thus might not be sensitive to changes af- 
fecting the residues at both P1 or P2 and P8. In support of 
this  interpretation,  we  recently observed that  a  MAGE- 
1.A1 variant peptide incorporating the photoactivatable de- 
rivative iodo,  azido  salicylic  acid  (IASA)  at  P1  was  effi- 
ciently recognized by CTL 258/8 but not by CTL 253/47. 
In contrast, a peptide with IASA at P8 could be recognized 
by CTL 253/47 but not by CTL 258/8.  Moreover, both 
variant peptides were recognized by CTL 82/30 (Luescher, 
I. F., and P. Romero, unpublished observations). Since the 
IASA  group  is  approximately twice  as  bulky  as  the  side 
chain of a tyrosine residue, these observations highlight the 
apparent lack of influence of the nature of the side chains at 
positions 1 or 8 on the efficiency ofpeptide recognition by 
different CTL clones. They suggest that the different TCR 
studied here may indeed have different "footprints" on the 
antigenic ligand. 
The diversity of recognition by CTL is associated with a 
diverse  TCR  gene  usage.  However,  somewhat  surpris- 
ingly, the structural diversity of TCR  appears here to be 
very high, inasmuch as the CDR3 sequences differ widely 
from one TCR to another. In another study in which CTL 
clones  specific  for  an  influenza  peptide  associated  with 
HLA-B27 were also differentially sensitive to conservative 
and  nonconservative  amino  acid  substitutions  at  peptide 
positions 1, 4, and 8, their TCR were found to be less di- 
verse (26, 27). 
Detailed analyses ofmurine TCR repertoires specific for 
a variety of antigenic peptides presented by class I or class II 
MHC molecules have shown that they can be either rela- 
tively homogeneous, in terms of the germline V, (D), andJ 
gene  segments  used  and  of the  primary  structure  of the 
junctional regions (28-34),  or, on the contrary, highly di- 
verse (35-38). The differences did not depend on the na- 
ture  of the  presenting  MHC  molecule alone,  since both 
homogeneous and diverse TCR repertoires were found in 
collections of CTL clones recognizing two unrelated anti- 
genic peptides presented by the same MHC  class I mole- 
cule (34,  36). In at least two of these studies, the diversity 
of TCR usage was correlated with a multiplicity of epitopes 
recognized on the same MHC-peptide complex (35,  39). 
Human CTL repertoires specific for class 1-restricted viral 
peptides were recently shown to be very limited; similar or 
even identical ot/[3 TCR primary structures were found in different individuals  sharing the presenting HLA allele  (26, 
40-43). 
The reasons for these so far unpredictable  degrees of di- 
versity  of TCR  repertoires  are  not  yet  well  understood, 
and at least two types of explanations have been proposed. 
On one hand,  it was suggested that there could be a rela- 
tionship  between  the  limited  diversity  of the  repertoire 
against a given peptide and homologies of  its sequence with 
a self-peptide. In this context, tolerance would greatly limit 
the diversity of the repertoire specific for antigenic peptides 
homologous to self (44).  On the other hand, limited TCR 
diversity  could  be  the  result  of a  continuous  selection  of 
certain  TCR.  during  persistent  infections  such  as  those 
caused by HIV (41)  or EBV (42).  Along these lines,  it has 
also  been  proposed  that  the  limited  heterogeneity  of the 
TCR.  expressed  by  "public"  clones,  which  are  reproduc- 
ibly  isolated  from  different  individuals  in  certain  experi- 
mental  models,  would  be  the  hallmark  of an  antigen-se- 
lected high a~nity T  cell response. Accordingly, such public 
clones would not be encountered in the repertoire specific 
for a  self-antigen  where,  due  to  tolerance  mechanisms,  a 
low affinity T  cell response would be expected (45). 
Peptide MAGE-1.A1 is a self-peptide, but gene MAGE-1 
appears  not  to  be  expressed  in  adult  normal  tissues,  with 
the exception of testis.  It is a likely possibility that it is ex- 
pressed in testis by germinal cells that do not express class I 
molecules.  Whether  gene MAGE-I  is  expressed  earlier in 
development  in  such  a  way  that  peptides  derived  from 
MAGE proteins could contribute to shaping the immuno- 
logical repertoire is unknown. 
The degree of diversity of TCR  repertoires  specific for 
tumor antigens  (46,  47)  is relevant  to the  development  of 
specific cancer immunotherapy that consists of immunizing 
cancer patients  against defined antigens  expressed  on their 
tumor  cells.  One  may  envision  that  tumor-specific  CTL 
expressing a  high-affinity TCR.  might out-compete other 
clones,  thus  leading  to  the  establishment  of a  highly  re- 
stricted but potent antitumor T  cell response that could be 
monitored  in vitro  by TCP,  usage analysis.  Alternatively, 
the broad repertoire ofanti-MAGE-l.A1  CTL specificities 
may prove to be a general phenomenon.  If this is the case, 
it  decreases  the  possibility  for a  tumor to  escape  through 
small  antigenic  variations  and  augments  the  possibility  of 
immunized patients  to mount a successful tumor rejection 
response. 
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